Telix Pharmaceuticals Limited
Pipeline14 assets
- 177Lu rosopatamab tetraxetanTLX591-Tx / PSMA / Antibody / Urologic OncologyProstate Cancer
- 177Lu-DOTA-PSMATLX597-Tx / PSMA / Small molecule / Urologic OncologyProstate Cancer
- 177Lu-girentuximabTLX250-Tx / CAIX / Antibody / Urologic OncologyKidney Cancer / ccRCC
- 131I-IPATLX101-Tx / LAT / Small molecule / Neuro-oncologyBrain Cancer / Glioma
- 90Y-besilesomabTLX66-Tx / CD66 / Antibody / HematologyBone-marrow conditioning
- 225Ac-RADmAbTLX592-Tx / PSMA / Antibody / Urologic OncologyProstate Cancer
- 225Ac-girentuximabTLX252-Tx / CAIX / Antibody / Urologic OncologyKidney Cancer
- UndisclosedTLX400-Tx / FAP / Small molecule / Urologic OncologyBladder Cancer
- 211At-APATLX102-Tx / LAT / Small molecule / Neuro-oncologyBrain Cancer
- -olaratumab conjugateTLX300-Tx / PDGFRα / Antibody / Musculoskeletal OncologySoft Tissue Sarcoma
- 153Sm-DOTMPTLX090-Tx / Small molecule / Musculoskeletal OncologyBone metastasesPain palliation
- 68Ga-PSMA-11TLX591-CDx / Illuccix / Gozellix / PSMA / Diagnostic Radiopharmaceutical / OncologyProstate Cancer Imaging
- 18F-floretyrosineTLX101-CDx / Pixclara / Pixlumi / LAT / Diagnostic Radiopharmaceutical / Neuro-oncologyGlioma Imaging
- 89Zr-DFO-girentuximabTLX250-CDx / Zircaix / CAIX / Diagnostic Radiopharmaceutical / OncologyClear Cell Renal Cell Carcinoma (ccRCC) Imaging
Latest news25 items
All newsTelix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces an educational webinar exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma) and how theranostics may help
Telix and United Imaging Announce Strategic Theranostics Collaboration
Partnership to evaluate Telix’s innovative precision medicine products and candidates in combination with United Imaging’s advanced scanner platforms. Initial focus on TLX101-Px (Pixclara® 1, Floretyrosine F 18) in the U.S. Framework to support potential co-development, validation, and deployment
ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
Telix’s first-in-class lutetium radio antibody-drug conjugate (rADC) candidate, TLX591-Tx, demonstrates acceptable tolerability across all standard-of-care (SoC) combination cohorts, with no new safety signals. Findings support feasibility of TLX591-Tx in combination with contemporary SoC in
Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences
MELBOURNE, Australia and INDIANAPOLIS, May 27, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will participate in the upcoming William Blair 46 th Annual Growth Stock Conference in